Camber Pharmaceuticals Inc Recalls

Atovaquone Oral Suspension 750mg (Camber) – Microbial Contamination (2023)

Microbial Contamination of Non-Sterile Product: Objectionable organism, identified as Bacillus cereus, found in product during testing of repackaged product.

Class IHigh

FDAMar 13, 2023Nationwide• Camber Pharmaceuticals Inc.

Lacosamide Oral Solution (Camber) – Excipient Specification Fail (2022)

Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content

Class IIILow

FDADec 6, 2022Nationwide• Camber Pharmaceuticals, Inc

Losartan Potassium Tablets (Camber) – Impurity Detection (2019)

CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient

Stay Informed

Camber Pharmaceuticals Inc. Recalls

Recall Summary

Atovaquone Oral Suspension 750mg (Camber) – Microbial Contamination (2023)

Lacosamide Oral Solution (Camber) – Excipient Specification Fail (2022)

Losartan Potassium Tablets (Camber) – Impurity Detection (2019)

Losartan Potassium Tablets (Camber) – Impurity Detection (2019)

Losartan Potassium Tablets (Camber) – Impurity Detection (2019)